[Is the use of selective serotonin reuptake inhibitors associated with an increased risk of bleeding?].
Recent studies have shown that there may be an increased risk of upper gastrointestinal tract bleeding when patients use selective serotonin reuptake inhibitors (SSRIs). We have reviewed the available epidemiological papers on this subject. There is apparently an increased risk of clinically significant bleeding episodes in patients treated with SSRIs. Two papers report a multiplicative interaction for combined treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and SSRIs. We conclude that SSRIs should be used with caution in patients with an increased risk of bleeding.
Dall
Michael
M
Odense Universitetshospital, Medicinsk Gastroenterologisk Afdeling S, og Syddansk Universitet, Odense, Institut for Klinisk Farmakologi. mdall@health.sdu.dk
Hallas
Jesper
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D004357:Drug Synergism; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D017367:Selective Serotonin Reuptake Inhibitors